# Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy

> **NCT01180959** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 45 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT01180959
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-14
- **Primary completion:** 2021-05-19
- **Final completion:** 2021-05-19
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2022-11-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01180959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01180959, "Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01180959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*